Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newer Rheumatoid Arthritis Drugs: Harmful On The Liver?

27.10.2003


Results of 41,885 Patient Analysis Announced at the American College of Rheumatology Annual Scientific Meeting



The disease modifying anti-rheumatic arthritis drug (DMARD), leflunomide does not have a higher risk of liver side effects than the traditional drug, but other newer DMARDs may, according to investigators at the Research Institute of the McGill University Health Center (MUHC). Their findings, presented today at the American College of Rheumatology Annual Scientific Meeting, show that this drug, leflunomide, has a similar effect on the liver as the traditional drug, methotrexate, and that newer biologic DMARDs may have greater risks.

“We decided to look specifically at the effect of leflunomide on the liver because of recent spontaneous reports with this drug,” said MUHC Director of Clinical Epidemiology Dr. Samy Suissa and lead investigator of the study. “We found that patients taking leflunomide had the same risk of hepatic events than patients taking methotrexate.”
Rheumatoid arthritis, a chronic inflammatory disease of joints and other internal organs, affects one out of 100 Canadians, and affects two million Americans. It leads to swelling, pain, stiffness, and possible loss of function and deformity of these joints. Treatments for rheumatoid arthritis are increasingly effective in slowing down this debilitating disease but their side effects can cause other health problems.


Dr. Suissa, also a professor at McGill University, and colleagues looked at data obtained from two large American health insurance companies that included 41,885 DMARD users. The DMARDs dispensed included leflunomide, the newer biologic DMARDs, methotrexate and other traditional DMARDs. Their study shows that the risk of serious hepatic events was significantly increased only with biological modifier DMARDs, not with leflunomide or other DMARDs.

“Evaluative studies such as these are extremely important in determining the best treatment options for patients while avoiding harm,” said Suissa. “Our findings suggest the hepatic side effects observed with the biologic DMARDs must be investigated further.”

The study was supported by Aventis, the makers of leflunomide.

For more information, please contact:
Christine Zeindler, MSc
Communications Coordinator (Research)
McGill University Health Centre Communications Services
www.muhc.ca
(514) 934-1934 ext. 36419
pager: (514) 406-1577

Leslie Anderson
onsite contact
mobile 917-370-6924

Christine Zeindler | MUHC
Further information:
http://www.muhc.ca

More articles from Health and Medicine:

nachricht New approach towards an improved treatment of anxiety disorders
12.12.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

nachricht Researchers image atomic structure of important immune regulator
11.12.2018 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Innovative Infrared heat reduces energy consumption in coating packaging for food

12.12.2018 | Trade Fair News

New Foldable Drone Flies through Narrow Holes in Rescue Missions

12.12.2018 | Information Technology

Obtaining polyester from plant oil

12.12.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>